Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03324932
Other study ID # CQARD-EBS-160402
Secondary ID jRCTs051180211
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date September 25, 2017
Est. completion date December 2027

Study information

Verified date October 2023
Source Kyoto Prefectural University of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This multicenter, randomized, comparative study will evaluate the efficacy of denosumab to prevent the adjuvant therapy of aromatase inhibitors-induced loss of bone mineral density (BMD) in breast cancer patients with normal BMD. Investigators will compare the inhibitory effects of denosumab on bone loss between participants with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy for stage I-IIIA postmenopausal hormone-sensitive breast cancer and controls.


Description:

Normal BMD means T score is ≥-1.0 for the lumbar vertebrae (L1-L4) and/or the femoral neck.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 160
Est. completion date December 2027
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender Female
Age group 20 Years and older
Eligibility Inclusion Criteria: Patients must meet all of the following items at the time of case registration: 1. Patients with infiltrative breast cancer, aged =20 years, meeting the following definitions: - Those pathologically diagnosed with stage I, II, or IIIA breast cancer (Cancer Management Regulations, 11th version) - Those who underwent appropriate surgery, such as mastectomy and breast-preserving surgery 2. Estrogen receptor (ER)- or progesterone receptor (PgR)-positive patients on immunohistochemical (IHC) staining 3. Females meeting one of the following criteria for menopause: - Those, aged =55 years, without menstruation - Those, aged <55 years, with amenorrhea for =12 months, or those diagnosed with menopause by attending physicians based on the FSH and estradiol levels - Those who underwent bilateral oophorectomy 4. Patients in whom the BMD for the lumbar vertebrae (L1-L4) on DXA before the start of this study is =-1.0SD of the mean value of young adult females (YAM), and the BMD for the femoral neck is =-1.0SD of YAM 5. Patients without lumbar vertebral or femoral fracture 6. Those with an ECOG PS of 0-2 7. Those with adequate organ functions (laboratory data within 4 weeks before case registration) - Leukocyte count, =3,000/mm3 or Neutrophil count, =1,500/mm3 - AST, ALT, =1.5-fold of the upper limit of the institutional reference range - Serum creatinine, =1.5-fold of the upper limit of the institutional reference range 8. Case registration should be performed before the following point:Twelve weeks after the completion of surgery or postoperative chemotherapy (The completion of chemotherapy refers to the completion of the final course, involving the recovery phase.) 9. Patients with an interval of =4 weeks after the discontinuation of therapy with bisphosphonates (oral preparations), estrogen preparations, raloxifene, calcitonin preparations, vitamin K preparations, active vitamin D preparations, or ipriflavone preparations, which influence bones 10. Those from whom written informed consent regarding study participation was obtained Exclusion Criteria: Whether each patient meets any of the following items must be checked on case registration: 1. Patients in whom distant metastasis was confirmed clinically or using imaging procedures at the time of case registration 2. Those with bilateral breast cancer 3. Those for whom postoperative hormonal therapy was started before consenting to study participation 4. Those who received endocrine therapy within 52 weeks before consenting to study participation 5. Those to whom bisphosphonate preparations were intravenously administered within 52 weeks before consenting to study participation 6. Those with the following diseases that may affect DXA - Severe scoliosis, immobility, hyperostosis or osteosclerosis of the lumbar vertebrae, calcification of the abdominal aorta, and vertebral disease 7. Those with a history of malignant tumors other than breast cancer within 260 weeks before consenting to study participation 8. Those with dental diseases, such as infectious diseases of the teeth or jaw and tooth trauma. Those for whom tooth or jaw surgery is scheduled within 6 weeks after consenting to study participation (tooth extraction, implantation) 9. Others who are considered to be ineligible by the chief investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Denosumab Injection
AI intake + denosumab injection per 6 months VS only AI intake

Locations

Country Name City State
Japan Hisako Ono Kyoto

Sponsors (1)

Lead Sponsor Collaborator
Kyoto Prefectural University of Medicine

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K, Matsuda T, Kato M, Ishikawa T, Yamada K, Yoshimura M, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Niikura N, Hasegawa Y, Miura D, Konishi E, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results. Breast Cancer. 2019 Jan;26(1):106-112. doi: 10.1007/s12282-018-0896-y. Epub 2018 Jul 27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary percentage change in the bone mineral density (BMD) for the lumbar vertebrae (L1-L4) on dual-energy X-ray absorptiometry (DXA) The change is a value obtained by subtracting 1 from the BMD after 12 months/baseline BMD is expressed as a percentage 12 months after the start of this study
Secondary percentage change in the BMD for the lumbar vertebrae (L1-L4) on DXA percentage change in the BMD for the femoral neck: After 2/3/4/5 years after 2, 3, 4, and 5 years
Secondary percentage change in the BMD for the femoral neck percentage change in the BMD for the femoral neck: After 12 months and 2/3/4/5 years after 12 months and 2/3/4/5 years
Secondary percentage change in the BMD for the radius (an ultrasonic bone densimeter is used)institutions in which ultrasonic bone densimeters are used) percentage change in the BMD for the radius (an ultrasonic bone densimeter is used): After 2 and 4 weeks, every 4 weeks thereafter (for 2 years after registration)(only institutions in which ultrasonic bone densimeters are used) after 2 and 4 weeks, every 4 weeks thereafter (for 2 years after registration)(only
Secondary Changes in Ca and bone metabolism markers Changes in Ca (mg/dL corrected by albumin level) and bone metabolism markers such as TRAP5b, bone-specific alkaline phosphatase (BSAP), blood pentosidine) by blood sampling at every 6 months after 24 weeks
Secondary Appearance rate of morbid fracture in all participants Appearance rate of morbid fracture up to 3 years in all participants. Morbid fractures include all types of fractures. up to 3 years
Secondary Disease-free survival Disease-free survival at the end of the study at least 5 year
Secondary Overall survival Overall survival at the end of the study at least 5 year
Secondary Appearance of adverse events Appearance rate of adverse events (such as hypocalcemia and necrosis of the jaw) at least 5 year
Secondary Quality of life (QOL) Quality of life(QOL), Japanese version Euro-Qol (EQ-5D-5L) evaluated by questionnaire at every 6 months after 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A